HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
pentamethylmelamine
RN given refers to parent cpd
Also Known As:
pentamethylmelamine hydrochloride; pentamethylmelamine monohydrochloride; N,N,N',N',N''-pentamethyl-1,3,5-triazine
Networked:
15
relevant articles (
0
outcomes,
3
trials/studies)
Bio-Agent Context: Research Results
Heterocyclic Compounds: 198
1-Ring Heterocyclic Compounds
Triazines: 306
Altretamine: 238
pentamethylmelamine: 15
Related Diseases
1.
Neoplasms (Cancer)
01/01/1980 - "
Phase I trial of pentamethylmelamine in patients with previously treated malignancies.
"
01/01/1983 - "
Pentamethylmelamine (PMM) 80 mg/m2 was administered I.V. to 8 patients during surgical resection of intracerebral tumors.
"
09/01/1981 - "
Pentamethylmelamine (PMM) is a water-soluble monodemethylated derivative of hexamethylmelamine and has a similar spectrum of activity against murine tumors.
"
07/01/1981 - "
Plasma pharmacokinetics of hexamethylmelamine (HMM) and pentamethylmelamine (PMM) were investigated after ip administration of doses of 50 or 100 mg/kg to M5076/73A ovarian tumor-bearing C57BL/6J female mice.
"
08/01/1980 - "
An early clinical trial of pentamethylmelamine (PMM) the monodemethylated derivative of hexamethylmelamine, was conducted in 22 adults with solid tumors.
"
2.
Sarcoma (Soft Tissue Sarcoma)
09/01/1984 - "
Biochemical studies on the ability of pentamethylmelamine to interact in vivo with DNA and proteins in a sensitive murine ovarian reticular cell sarcoma.
"
3.
Carcinoma (Carcinomatosis)
05/01/1984 - "
Randomized phase II trial of hexamethylmelamine versus pentamethylmelamine in carcinoma of the bilharzial bladder.
"
4.
Ovarian Neoplasms (Ovarian Cancer)
01/01/1982 - "
The distribution of hexamethylmelamine (HMM), pentamethylmelamine (PMM), and their metabolites N2,N2,N4,N6-tetramethylmelamine (TMM) and N2,N4,N6-trimethylmelamine (TriMM) was investigated in different tissues of M5076/73A ovarian cancer-bearing mice given 100 mg/kg ip of either drug.
"
01/01/1982 - "
Hexamethylmelamine and pentamethylmelamine tissue distribution in M5076/73A ovarian cancer-bearing mice.
"
01/01/1981 - "
Pentamethylmelamine, mitomycin C, methyl-GAG, and AMSA were relatively ineffective in ovarian cancer.
"
04/01/1980 - "
The cytotoxicity of hexamethylmelamine (HMM) and its metabolites pentamethylmelamine (PMM), N,2,2,4,6-tetramethylmelamine (TMM) and hydroxymethylpentamethylmelamine (HMPMM) and of the alkylating agent triethylenemelamine (TEM) were studied on a cell line derived from a human ovarian cancer, by measuring [3H]TdR uptake.
"
5.
Plasmacytoma
04/01/1984 - "
Two analogues, namely pentamethylmelamine (PMM) and 2,2,4,4-tetramethylmelamine (TMM), and hexamethylmelamine (HMM) itself were shown to be active towards the murine ADJ/PC6A (PC6) plasmacytoma; another three, 2-chloro-4,6-bis(dimethylamino)-1,3,5-triazine (CBDT), 2,4-bis-(dimethylamino)-6-hydrazino-1, 3,5-triazine (HBDT) and 2,4,6-trimethylmelamine (TriMM) were inactive against the same tumour.
"
Related Drugs and Biologics
1.
Altretamine (Hemel)
2.
DNA (Deoxyribonucleic Acid)
3.
Proteins (Proteins, Gene)
4.
Mitomycin (Mitomycin-C)
5.
Triethylenemelamine (Tretamine)
6.
Procarbazine (Matulane)
7.
Mitoguazone (MGBG)
8.
Amsacrine (AMSA)
9.
Alkylating Agents
10.
PC6 extract (PC6)
Related Therapies and Procedures
1.
Injections